Cargando…
Does the Immunocompetent Status of Cancer Patients Have an Impact on Therapeutic DC Vaccination Strategies?
Although different types of therapeutic vaccines against established cancerous lesions in various indications have been developed since the 1990s, their clinical benefit is still very limited. This observed lack of effectiveness in cancer eradication may be partially due to the often deficient immun...
Autores principales: | Martin Lluesma, Silvia, Graciotti, Michele, Chiang, Cheryl Lai-Lai, Kandalaft, Lana E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6313858/ https://www.ncbi.nlm.nih.gov/pubmed/30477198 http://dx.doi.org/10.3390/vaccines6040079 |
Ejemplares similares
-
IL-15 and a Two-Step Maturation Process Improve Bone Marrow-Derived Dendritic Cell Cancer Vaccine
por: Mookerjee, Ananda, et al.
Publicado: (2019) -
A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2018) -
Correction: A cancer vaccine with dendritic cells differentiated with GM-CSF and IFNα and pulsed with a squaric acid treated cell lysate improves T cell priming and tumor growth control in a mouse model
por: Mookerjee, Ananda, et al.
Publicado: (2019) -
Whole Tumor Antigen Vaccines: Where Are We?
por: Chiang, Cheryl Lai-Lai, et al.
Publicado: (2015) -
Cancer Vaccines in Ovarian Cancer: How Can We Improve?
por: Martin Lluesma, Silvia, et al.
Publicado: (2016)